Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers

Tumor Biology

Volumn 26, Issue 6, 2005, Pages 324-336

  Sidiropoulos, Michael ^a,b   Pampalakis, Georgios ^c   Sotiropoulou, Georgia ^c   Katsaros, Dionyssios ^d   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PATRAS   (Greece)

^d UNIVERSITY OF TURIN   (Italy)

Author keywords

Breast cancer; CpG islands; KLK10 NES1; Methylation; Ovarian cancer; Prostate cancer

Indexed keywords

KALLIKREIN; KALLIKREIN 10; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; GENE IDENTIFICATION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; UPREGULATION;

EID: 27744571741     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089290     Document Type: Article

References (36)

1. Sager R: Tumor suppressor genes: the puzzle and the promise. Science 1989;246:1406-1412.
2. Gardiner-Garden M, Frommer M: CpG islands in vertebrate genomes. J Mol Biol 1987;196:261-282.
3. Strathdee G, Brown R: Aberrant DNA methylation in cancer: potential clinical interventions. Exp Rev Mol Med 2002;4:1-17.
4. Ehrlich M, Gama-Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA, Gehrke C: Amount and distribution of 5-methylcytosine in human DNA from different types of cells. Nucleic Acids Res 1982;10:2709-2721.
5. Bird AP: CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-212.
6. Yan L, Yang X, Davidson NE: Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia 2001;6:183-192.
7. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985;228:187-190.
8. Momparler RL, Bovenzi V: DNA methylation and cancer. J Cell Physiol 2000;183:145-154.
9. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-692.
10. Jones P, Laird PW: Cancer epigenetics comes of age. Nat Genet 1999;21:163-167.
11. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95:6870-6875.
12. Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, Palazzo JP, Fishel R, Goodfellow PJ: MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 1999;8:661-666.
13. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-692.
14. Yousef GM, Diamandis EP: The new human tissue kallikrein gene family: structure, function and association to disease. Endocr Rev 2001;22:184-204.
15. Diamandis EP, Yousef GM, Luo L, Magklara A, Obiezu CV: The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol Metab 2000;11:54-60.
16. Aznavoorian S, Murphy AN, Stetler-Stevenson WG, Liotta LA: Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71:1368-1383.
17. Matrisian LM: Cancer biology: extracellular proteinases in malignancy. Curr Biol 1999;9:R776-R778.
18. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
19. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-1149.
20. McCawley LJ, Matrisian LM: Tumor progression: defining the soil round the tumor seed. Curr Biol 2001;11:R25-R27.
21. Liu XL, Wazer DE, Watanabe K, Band V: Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 1996;56:3371-3379.
22. Luo LY, Grass L, Howarth DJC, Thibault P, Ong H, Diamandis EP: Immunofluorometric assay of human kallikrein 10 and its detection in biological fluids and tissues. Clin Chem 2001;47:237-246.
23. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V: The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 1996;58:4782-4786.
24. Li B, Goyal J, Dhar S, Dimri G, Evron E, Sukumar S, Wazer DE, Band V: CpG methylation as a basis for breast tumor-specific loss of NES1/kallikreins 10 expression. Cancer Res 2001;61:8014-8021.
25. Bharaj BB, Luo LY, Jung K, Stephan C, Diamandis EP: Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. Prostate 2002;51:35-41.
26. Luo LY, Rajpert-De Meyts ER, Jung K, Diamandis EP: Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br J Cancer 2001;85:220-224.
27. Luo LY, Katsaros D, Scorilas A, Fracchioli S, Bellino R, Van Gramberen M, de Bruijn H, Henrik A, Stenman UH, Massabrio M, van der Zee AG, Vergote I, Diamandis EP: The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003;63:807-811.
28. Gardiner-Garden M, Frommer M: CpG islands in vertebrate genomes. J Mol Biol 1987;196:261-282.
29. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-9826.
30. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S: Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 1995;92:7416-7419.
31. Momparler RL: Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine. Pharmacol Ther 1985;30:287-299.
32. Yuan BZ, Durkin ME, Papescu NC: Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet 2003;140:113-117.
33. Tuxen MK, Soletormos G, Dombernowsky P: Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev 1995;21:215-245.
34. 6- methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001;3:939-942.
35. Patel A, Groopman JD, Umar A: DNA methylation as a cancer-specific biomarker: from molecules to populations. Ann NY Acad Sci 2003;983:286-297.
36. Ioshikhes IP, Zhang MQ: Large-scale human promoter mapping using CpG islands. Nat Genet 2000;26:61-63.